BEACON-IPF: Can a new drug bexotegrast help slow disease progression in people with idiopathic pulmonary fibrosis?

Upcoming study
Expected to open November 2023
This study is currently recruiting
Expected to close
This study is closed
This study closed in
We will update this page with study results when available.
Information on study results are included below
This study closed in
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

Scientists are investigating the causes of pulmonary fibrosis to help develop new treatment options. Higher levels of certain molecules in the lungs are related to the development of pulmonary fibrosis.

Higher levels of molecules called integrins are found in the lung tissue of IPF patients. A new drug bexotegrast may help to block the role of integrins in the scarring process and slow disease progression.

In this next phase of research, scientists want to find out more about the safety and effectiveness of this drug in people living with idiopathic pulmonary fibrosis and investigate the potential effects on lung function decline, symptom improvement, and quality of life changes.

 – 

What is involved?

You will be randomly placed into 1 of 3 groups. Groups 1 and 2 will receive a higher or lower dose of bexotegrast. Group 3 will receive a placebo. A placebo is something that looks exactly like the drug, but there are no active ingredients. All 3 groups will take tablets by mouth, once per day.

Throughout the duration of the study, you will be asked to visit the hospital 8 times. This will be complementary to your standard health care. The healthcare and research team will assess your health and carry out tests including: breathing tests to measure your lung function, blood tests, urine tests, medical scans and health-related questionnaires.

You may be able to receive reimbursement for your travel, parking and food expenses during the hospital visits.

Summary of involvement

Study duration for 1 year

8 hospital visits

Taking tablets once daily

Breathing tests

Blood tests

Medical scans

Urine tests

Questionnaires

Can I take part?

You may be able to take part if you are aged over 40 years and older, and have a diagnosis of IPF and have received your diagnosis within the last 7 years.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the research team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Aged 40 years and over

Diagnosis of IPF within the last 7 years

You can take part if you are currently taking a stable dose of the antifibrotic medications, nintedanib or pirfenidone for at least 12 weeks

If you are not taking antifibrotic medications, you must not have taken them for at least 8 weeks before the study starts

There is a set criteria for lung function, but this will be assessed by the research team

You will not be able to join the study of any of the following applies:

Taking medication for pulmonary hypertension

Current smoker

History of cancer within the last 5 years

Pregnant or breastfeeding women

Previous use of the study drug, bexotegrast

Acute exacerbation of IPF within the last 6 months

If you are likely to have a lung transplant during the study

What difference could taking part make?

Taking part in this study will help researchers to understand if bexotegrast could be an effective treatment option which slows down the rate of lung function decline.

Where does the study take place?

Study locations

Birmingham

Cambridge

Cottingham

Edinburgh

London

Londonderry

Oxford

Peterborough

Southampton

Wakefield

How to take part

Please speak to your medical team about taking part, or contact the research team directly, to express your interests.

For more information, you can take a look at the BEACON-IPF website.

Further information

This page is a summary which provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

clintrials@pliantrx.com

This study is supported by

Pliant Therapeutics, Inc.
Study ID number:
NCT06097260

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org